# A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)

> **NCT07716618** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** SAL0120 1mg
- **DRUG:** SAL0120 2mg
- **DRUG:** SAL0120 4mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07716618
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-17
- **Primary completion:** 2026-05-27
- **Final completion:** 2026-08-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716618, "A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*